LOGIN  |  REGISTER
Recursion

Baxter to Present at 2023 Wells Fargo Healthcare Conference

August 22, 2023 | Last Trade: US$30.29 0.48 1.61

DEERFIELD, Ill. / Aug 22, 2023 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2023 Wells Fargo Healthcare Conference on Thursday, September 7, 2023. José (Joe) E. Almeida, Baxter’s chairman, president and chief executive officer is scheduled to present at 8:45 a.m. EST.

The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through March 5, 2024.

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

Viking Therapeutics

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page